West Pharmaceutical beats Q2 estimates by 14%, lifts full-year outlook

West Pharmaceutical Services reported Q2 adjusted EPS of $2.37, beating the $2.08 consensus by 14 percent, on revenue of $872.3 million.

The company raised its full-year adjusted EPS guidance to a range of $8.85 to $9.05 per share, up from a prior midpoint of $8.50, reflecting confidence in demand for its pharmaceutical packaging and containment systems. Full-year revenue is now expected between $3.35 billion and $3.38 billion, up from a prior midpoint of $3.32 billion.

Metric	Actual	Consensus	Beat/Miss
Revenue	$872.3M	$836.8M	+4.2%
Adjusted EPS	$2.37	$2.08	+13.9%

Revenue of $872.3 million topped the Zacks Consensus Estimate of $836.8 million by 4.2 percent and climbed 14 percent from $766.5 million a year earlier. On a GAAP basis, net income was $154 million, or $2.15 per share, compared with $132.3 million, or $1.84 per share, in the year-ago quarter. Adjusted operating margin expanded 1.5 percentage points to 21.8 percent. The company has surpassed consensus EPS estimates in each of the past four quarters.

Founded in 1923, West Pharmaceutical is a critical link in the pharmaceutical supply chain, manufacturing specialized packaging, containment systems and delivery devices for injectable drugs. The company operates in the medical-dental supplies industry and counts major pharmaceutical companies among its customers.

Shares rose 7.3 percent to $384.97 in after-hours trading, bringing the stock's year-to-date gain to 30 percent — more than triple the S&P 500's 9.6 percent advance. For the current quarter, West Pharmaceutical forecast revenue of $820 million to $835 million and adjusted EPS of $2.14 to $2.24.

The favorable trend in earnings estimate revisions ahead of the report supported a Zacks Rank #2 (Buy) rating for the stock. The guidance increase reflects management's expectation of sustained demand for its injectable drug packaging and containment systems. Investors will watch the Q3 earnings call for updates on segment margins and the pace of new product adoption.

This article is for informational purposes only and does not constitute investment advice.